Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment

Topic Information

Dear Colleagues,

Recent advances in antibody-mediated therapy have significantly improved its therapeutic efficacy in many types of cancer. Antibody-mediated therapy includes the following:

1. Monoclonal antibodies against specific targets associated with cancer cell survival, progression, metastasis, and drug resistance;
2. Monoclonal antibodies against specific targets that are relatively highly expressed in cancer cells or are cancer-specific, regardless of cancer cell survival progression, metastasis, or drug resistance;
3. Monoclonal antibodies against specific targets in cancer cells or normal cells that modulate the tumor microenvironment, especially immune systems;
4. Antibody–drug conjugates (ADCs) are complex molecules consisting of antibodies conjugated to biologically active cancer cell-killing substances.

These antibody-mediated therapies have been widely used as combination therapies due to their synergistic effects with cytotoxic anticancer drugs. Eventually, ADCs, complex molecules consisting of antibodies and cytotoxic substances, were developed to improve treatment outcomes. However, the side effects of ADCs are very serious, requiring careful monitoring during treatment. Therefore, this Topic was prepared to deeply examine the efficacy, related mechanisms, and toxicities of the latest antibody-related therapies or other novel therapies for each cancer.

Scope of the Topic

1. Monoclonal antibodies as monotherapy, as antibody–drug conjugates (ADCs), or in combination with other drugs in cancer treatment:
2. Efficacy, mechanism of action, and treatment guidelines;
3. Predictive/prognostic biomarkers;
4. Toxicity and management.
5. Other emerging therapies in cancer treatment (CAR-T cell therapy, NK or other cell therapies, oncolytic virus therapy, cancer vaccines, targeted therapy, etc.). 

Dr. Won Sup Lee
Prof. Dr. Yaewon Yang
Prof. Dr. Seil Go
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Cancers cancers	4.4	8.8	2009	20.3 Days	CHF 2900	Submit
Current Issues in Molecular Biology cimb	3.0	3.7	1999	17.8 Days	CHF 2200	Submit
Current Oncology curroncol	3.4	4.9	1994	21.5 Days	CHF 2200	Submit
Scientia Pharmaceutica scipharm	2.5	4.6	1930	38.1 Days	CHF 1000	Submit
Antibodies antibodies	2.7	4.5	2012	22.2 Days	CHF 1800	Submit
International Journal of Molecular Sciences ijms	4.9	9.0	2000	20.5 Days	CHF 2900	Submit
International Journal of Translational Medicine ijtm	-	2.2	2021	25.9 Days	CHF 1000	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (3 papers)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Cancers CIMB Current Oncology Sci. Pharm. Antibodies IJMS IJTM

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

14 pages, 1987 KB  

Open AccessArticle

Combination Treatment of Carboxyl Esterase 2-Overexpressing hTERT-Immortalized Human Adipose Stem Cells Enhances the Inhibition of Tumor Growth by Irinotecan in PC3, a Castration-Resistant Prostate Cancer Model

by Jae Heon Kim, Miho Song, Jeongkun Lee, Sang Hun Lee and Yun Seob Song

Curr. Issues Mol. Biol. 2025, 47(11), 902; https://doi.org/10.3390/cimb47110902 - 30 Oct 2025

Viewed by 291

Abstract

Castration-resistant prostate cancer (CRPC) remains difficult to treat with conventional chemotherapy. We evaluated a stem cell-based enzyme-prodrug strategy using hTERT-immortalized adipose-derived stem cells engineered to express rabbit carboxylesterase 2 (hTERT-ADSC.CE2) in combination with irinotecan (CPT-11). hTERT-ADSC.CE2 cells were generated via lentiviral transduction and [...] Read more.

Castration-resistant prostate cancer (CRPC) remains difficult to treat with conventional chemotherapy. We evaluated a stem cell-based enzyme-prodrug strategy using hTERT-immortalized adipose-derived stem cells engineered to express rabbit carboxylesterase 2 (hTERT-ADSC.CE2) in combination with irinotecan (CPT-11). hTERT-ADSC.CE2 cells were generated via lentiviral transduction and confirmed to overexpress CE2. Their tumor-homing capacity toward PC3 prostate cancer cells was assessed, along with prodrug activation, apoptosis induction, and in vivo tumor suppression in a CRPC mouse model. hTERT-ADSC.CE2 cells demonstrated enhanced migration toward PC3 cells and higher expression of tumor-homing factors than the controls. Under CPT-11, they exhibited a strong “suicide” effect and induced selective killing of PC3 cells, with upregulation of BAX and cleaved caspase-3 and downregulation of BCL-2. By day 14, the combination arm showed significantly lower tumor burden than both the control and irinotecan-alone arms (p < 0.05). The pattern is consistent with intratumoral activation and localized SN-38 exposure. hTERT-ADSC.CE2 combined with irinotecan provides potent, tumor-targeted cytotoxicity and markedly suppresses CRPC progression. This cell-mediated prodrug activation system may represent a promising therapeutic approach for advanced prostate cancer. Full article

(This article belongs to the Topic Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment)

►▼ Show Figures

Figure 1

22 pages, 709 KB  

Open AccessReview

Recombinant Oncolytic Viruses: Hexagonal Warriors in the Field of Solid Tumor Immunotherapy

by Cong Zhang and Qian Sun

Curr. Issues Mol. Biol. 2025, 47(11), 878; https://doi.org/10.3390/cimb47110878 - 23 Oct 2025

Viewed by 877

Abstract

In the past decade, research on recombinant oncolytic viral agents in the treatment of solid tumors has evolved from the initial stage of simple genetic engineering to the current stage of multiple pipelines of parallel clinical application and combination therapy. Compared with T-VEC, [...] Read more.

In the past decade, research on recombinant oncolytic viral agents in the treatment of solid tumors has evolved from the initial stage of simple genetic engineering to the current stage of multiple pipelines of parallel clinical application and combination therapy. Compared with T-VEC, the classical therapeutic agent that only expresses GM-CSF, which was approved in 2015, most new oncolytic virus designs include diverse gene constructs to reduce toxic effects, enhance multiple antitumor immunity, avoid immune clearance, or enhance tumor targeting. The single route of administration that activates the inflammatory tumor immune microenvironment by intratumoral injection is no longer sufficient to meet the treatment needs of refractory solid tumors. In this review, we illustrated the construction patterns of typical recombinant oncolytic viral agents and their latest clinical trial progress. Secondly, we summarized the underlying mechanisms of the combined application of antiviral and antitumor immunity in the field of solid tumor immunotherapy. Finally, we explored the feasibility of the intravenous application of oncolytic viruses and their future development directions. We believe that the diversified treatment design of oncolytic viruses will bring more surprises to the immunotherapy of refractory tumors. Full article

(This article belongs to the Topic Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment)

►▼ Show Figures

Graphical abstract

attachment

Supplementary material:
Supplementary File 1 (ZIP, 3914 KB)

17 pages, 1957 KB  

Open AccessArticle

In Silico Multitarget Profiling of Non-Selective Beta-Blockers Highlights Their Potential as Key Agents in Breast Cancer Adjuvant Therapy via ADRB2, ERBB2, and NPYR Receptors

by Felipe Muñoz-González, José Correa-Basurto, Iván Ignacio-Mejia and Cindy Bandala

Curr. Issues Mol. Biol. 2025, 47(10), 789; https://doi.org/10.3390/cimb47100789 - 23 Sep 2025

Viewed by 496

Abstract

Breast cancer (BC) is associated with multiple molecular factors such as overexpression of the beta-2 adrenergic receptor (ADRB2) and the overproduction of its agonists (norepinephrine and epinephrine). The role of adrenergic signaling in BC highlights the therapeutic potential of non-selective beta-blockers (nsBBs) as [...] Read more.

Breast cancer (BC) is associated with multiple molecular factors such as overexpression of the beta-2 adrenergic receptor (ADRB2) and the overproduction of its agonists (norepinephrine and epinephrine). The role of adrenergic signaling in BC highlights the therapeutic potential of non-selective beta-blockers (nsBBs) as inhibitors of well-established protumor signaling pathways related to ADRB2 and their possible affinity for other important protumoral receptors. Our aim was to identify how nsBBs currently prescribed may also interact with receptors other than ADRB2, which are related to the pathophysiology of BC, using bioinformatic intracellular pathway analysis (BIPA). Subsequently, the affinity of nsBBs for both ADRB2 and the targets identified by BIPA was evaluated. We found that, beyond ADRB2, both receptor tyrosine kinase 2 (ERBB2) and neuropeptide Y receptor (NPYR) are promising targets for nsBBs in the adjuvant treatment of BC, according to BIPA. Docking studies showed that the nsBB with the highest binding affinity (ΔG) was carvedilol (−10.5 kcal/mol), followed by propranolol (−8.5 kcal/mol). These in silico findings suggest previously unrecognized pharmacological mechanisms for nsBBs in the possible treatment for BC. Notably, differences in receptor affinity were observed among the nsBBs, with carvedilol exhibiting the strongest binding affinity values on ADRB2, ERBB2, and NPYR as biological targets against BC cells. These promising results require future experimental validation. Full article

(This article belongs to the Topic Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-3